This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
Clinical Ink

Clinical Ink buys Digital Artefacts to boost neurocognitive trials business

Posted by on 15 November 2021
Share this article

Data and technology firm Clinical Ink has acquired Digital Artefacts, a developer of cognitive, behavioral, and physiological data analysis systems.

The takeover – financial terms of which were not disclosed – was prompted by a desire to enrich data generated during trials, according to Clinical Ink CEO Ed Seguine.

“The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments.”

He added that Digital Artefacts’ wearables and sensors acumen would provide provides instrumented data collection that complements our existing products and solutions.

Clinical Ink cited Digital Artefacts’ neurocognitive assessment and research tools, wearable technologies and expertise in data collection among the key benefits of the deal.

Therapeutic focus

The acquisition comes six months after Clinical Ink launched a suite of electronic clinical outcome assessments (eCOA) – measures that describes or reflects how a patient feels, functions, or survives.

The eCOAs include the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Vineland-3, Bayley-III, and several others that have never been implemented effectively in an electronic format.

At the time Seguine spoke about neurological assessments as an area of unmet need for the clinical trial sector.

“A significant share of the clinical trials industry is still relying on paper and pencil cognitive tests when electronic versions are available — versions that support not only better data quality but reduced timelines and cost."

He added that “Our complex eCOA scales and assessment implementations represent a new standard of trial execution simplicity and efficiency.”

Clinical Ink has also been building its business in other areas. In March, for example, the firm worked with US contract research organization (CRO) PPD to develop a review process for systemic lupus erythematosus (SLE).

The collaboration focused on enhancing data quality and making SLE studies more efficient.

Image: Stock Photo Secrets

Share this article

Sign up for Clinical Insider email updates